Psilocybin Compared With Escitalopram for Depression
No difference seen in change in depression scores at six weeks for psilocybin plus placebo versus psilocybin plus escitalopram
General Psychiatry
Xywav Gets Priority Review for Idiopathic Hypersomnia
The sNDA is supported by data from a phase 3 study that assessed Xywav in adults with idiopathic hypersomnia.
Considerable Neurologic, Psychiatric Morbidity Reported After COVID-19
Estimated incidence of neurological or psychiatric diagnosis was 33.62 percent among 236,379 patients
FDA Rejects Pimavanserin sNDA for Dementia-Related Psychosis
The sNDA submission was supported by data from the pivotal phase 3 HARMONY study.
Qelbree, a Nonstimulant Treatment for ADHD, Gets FDA Approval
The approval was based on data from an extensive development program that included four phase 3 studies involving more than 1000 patients 6 to 17 years of age with ADHD.
Review Examines Metabolic, Cardiovascular Side Effects of Second-Generation Antipsychotics
A systematic review examined the metabolic and cardiovascular adverse effects in commonly prescribed second-generation antipsychotics.
FDA: Risk of Arrhythmias With Lamotrigine in Patients With Heart Disease
Lamotrigine is indicated as monotherapy or adjunctive therapy for epilepsy and for use as maintenance treatment in patients with bipolar I disorder.
FDA: Abuse/Misuse of OTC Nasal Decongestant Can Lead to Major Health Complications
Since January 1, 2000, there have been 460 documented cases of propylhexedrine abuse or misuse reported to US poison control centers.
Poor Sleep, Burnout Increase COVID-19 Risk in Health Care Workers
Longer sleep duration linked to reduced odds of COVID-19; sleep problems, burnout linked to increased odds
Review: ß-Blocker Therapy Not Linked to Depression
ß-blocker therapy possibly associated with unusual dreams, insomnia, and sleep disorders
